General Information of Drug (ID: DM1EBRK)

Drug Name
FPA144 Drug Info
Indication
Disease Entry ICD 11 Status REF
Bladder cancer 2C94 Phase 1 [1]
Gastric adenocarcinoma 2B72 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM1EBRK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sucralfate DMP9HBO Acne vulgaris ED80 Approved [2]
Squalamine DM3PS2E Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
DVC1-0101 DMUGBQK Arteriosclerosis BD40 Phase 2 [4]
Bemarituzumab DMWNYIE Gastric adenocarcinoma 2B72 Phase 2 [5]
TGP-580 DMYN6G0 Neurodegenerative disorder 8A20-8A23 Discontinued in Phase 2 [6]
RG-8803 DMI0CYV Diabetic retinopathy 9B71.0 Terminated [7]
2-Sulfhydryl-Ethanol DMJBO3D Discovery agent N.A. Investigative [8]
N,O6-Disulfo-Glucosamine DMYCV7U Discovery agent N.A. Investigative [8]
BIBF100 DMUWO6D Multiple myeloma 2A83 Investigative [9]
1,4-Dideoxy-O2-Sulfo-Glucuronic Acid DM9KUQZ Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor-2 (FGF2) TTGKIED FGF2_HUMAN Antagonist [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
3 Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
4 DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
7 US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.